Glenmark Pharmaceuticals has launched TEVIMBRA (tislelizumab) in India following the approval by the Central Drugs Standard Control Organization (CDSCO).

TEVIMBRA is a uniquely designed anti-PD-1 monoclonal antibody developed by BeiGene (now BeOne Medicines). It is indicated for the treatment of first-line locally advanced or metastatic non-small cell lung cancer (NSCLC) in combination with chemotherapy and second-line treatment of locally advanced or metastatic NSCLC and esophageal squamous cell carcinoma (ESCC) as monotherapy.

This launch marks Glenmark's first foray into immune-oncology in India and is a major milestone in expanding its innovative oncology portfolio. NSCLC is the most common type of lung cancer, representing over 80 percent of all lung cancer cases. Similarly, ESCC is the most common histological subtype of esophageal cancer in India. TEVIMBRA caters to the needs of this significant patient population by offering a differentiated and proven treatment option for these cancers.

TEVIMBRA is approved and marketed in multiple leading global markets, including the United States, European Union, Australia and China. Designed to selectively bind to PD-1 receptors, TEVIMBRA restores T-cell function while minimising off-target immune suppression and has demonstrated robust efficacy with a favourable safety profile across diverse solid tumour types in multiple pivotal Phase 3 studies and through a comprehensive global clinical development program.

Commenting on the development, Alok Malik, President and Business Head – India Formulations, Glenmark Pharmaceuticals Ltd. said, “With the launch of TEVIMBRA, Glenmark is delivering on its commitment to transform cancer care in India by making globally benchmarked immunotherapies more accessible. At a time when the cancer burden is rising sharply, we are proud to enable oncologists and patients to access TEVIMBRA, a therapy with proven efficacy and safety outcomes, strong science, and meaningful impact. Immuno-oncology offers a promising future for the treatment of various types of advanced cancers, which are difficult to treat. Our foray in this area marks a significant inflection point in our journey to build a world-class oncology portfolio that is innovative, inclusive and at the same time life-changing for patients.”